Human liver xenotransplantation by Starzl, TE et al.
Although two men recently given baboon liver xenografts subsequently died, the cases provided valuable information 
on the effects of xenotransplantation in humans. Here, Tom Starzl and colleagues discuss these cases and 
the prospects for future attempts at baboon-to-human xenotransplantation. 
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On 28 June 1992 and on 10 January 1991 twO men aged 3S and 62 
years, respectively. with end-
stage chronic active hepatitis caused by 
hepatitis B virus (HBY) had their dis-
eased livers replaced with baboon hepatic 
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xenografts. As well as the worldwide 
shortage of donor organs. these efforts 
were prompted by eVidence that the 
baboon liver would be resistant to the 
HBV that reinfectS most allografts under 
comparable circumstance I • 
Comparison of cases 
Extensive infectious surveillance was 
performed. Both donors were healthy 
and were antibody-positive for foamy 
virus. Epstein-Barr virus (EBY). cyto-
megalovirus (CMy). and simian agent 8: 
in addition. donor I had antibodies 
against varrcella zoster virus. The 
donor/recipient weightS were 25.8170 kg 
in case I and 35.8/80.4 kg in case 2. The 
orthotopic transplantations were with 
the piggy-back technique. Postopera-
tively. there was histopathologic evi-
dence of rapid regeneration I and a 
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tripling or quadrupling of graft volume 
within 3-4 weeks. The conventional Iym-
phocytotoxic crossmatch of both recipi-
ent sera to their donor lymphocytes was 
positive in both cases but negative after 
dithiothreitol treatment. 
Both patients had ABO-compatible 
donors: A to A in case I and B to B in 
case 2. However. there were differences 
that might have had an impact on the 
efficacy of perioperative immune modu-
lation. Patient 2 was nearly twice as old 
and far more frail. He did not have 
splenectomy until the fourth postopera-
tive day whereas patient I had had a 
splenectomy 3 years previously. Both 
patients were immunocompetent. al-
though the first also had an human 
immunodeficiency virus (HIV) infection. 
Patient I awoke promptly from anes-
thesia. resumed diet and ambulation. and 
was jaundice-free for most of the 70 
days of survival. Tests of liver injury had 
only minor abnormalities. Prothrombin 
time and other clotting factors promptly 
normalized except for thrombocytopenia. 
Hypoalbuminemia «2 gm%) prompted 
human albumin infusions throughout I. 
In contrast. patient 2 remained icteric 
(Fig. I) and comatose after the operation. 
Patient I developed renal failure after 21 
days. and patient 2 became anuric imme-
diately after the transplantation. 
The cause of death in both cases was 
multifactorial. the proximate premortem 
events being a ruptured mycotic aneur-
ysm (Aspergillus) of a cerebral artery in 
patient I and peritonitis in patient 2 sec-
ondary to an anastomotic leak at the 
jejune-jejunostomy of the Roux-y biliary 
reconstruction. 
Questions about rejection 
The two recent cases were not in 
terra rncognita except for the fact that the 
liver was the xenograft. Nearly 30 years 
ago, It was shown that baboon kidney 
xenograft relection in humans under aza-
thioprine-prednisone immunosuppres-
sion2 resembled the renal allograft rejec-
tion that occurs In reCipients who have 
preformed anti-donor antlbodiesl . The 
six transplanted baboon kidneys In the 
earlier expenence survived 6 to 60 days. 
In all six there was fierce cellular rejec-
tion plus a presumably antibody-mediated 
(humoral) occlusive endotheliolitis of the 
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FIGURE 1 
Oinical course of second baboon liver recrplent SM, solumedrof (methlypredmsolone); PG£. 
pros!Oglandin E; 8X, biopsy. 
graft microvasculature2. In turn the distal 
ischemia caused by the vascular injury 
appeared to be responSible for patchy 
gangrene of the xenografts, interspersed 
between islands of still functional 
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parenchyma. Similar histopathologic find-
ings were reported more than 20 years 
later after cardiac xenotransplantation 
under a cyclosporine-based immunosup-
pressive reglmen 4• 
FIGURE 2 
uver xenografi biopsy from pOllent 2. obtained 
on day 23 (the same day as the repaIr of the 
incestJnal anaS!ornol/C leo/d. showed no eVIdence 
of rejection. Note intoct bile ducts and tho/eno-
SIS (3 15 x ongrnol magmficatJon. H&E). 
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Effectiveness of the FK506-based drug 
cocktail 
The cellular as well as humoral (vas-
cular) rejection that destroyed all of the 
earlier baboon kidney and heart grafts 
was prevented in the two recent liver 
xenografts with a four-drug cocktail of 
FK506. prednisone. perioperative prosta-
glandin EI• and a short course of cyclo-
phosphamide I. The value of cyclophos-
phamide and other anti-metabolites in 
the interdiction of the xenospecific vas-
cular injury had been seen in hamster-
to-rat heart and liver transplantsS,6, After 
breaking through the antibody barrier in 
the animal model. chronic treatment 
with FKS06 or cyclosporine alone 
allowed the rat recipients of both organs 
to survive indefinitely, 
Because it was suspected that the 
first reCipient had been over-immuno-
suppressed. mainly as the result of a 40-
day course of cyclophosphamide I • the 
latter drug was given in lower doses for 
only 10 days in patient 2 (Fig, I), When 
the jaundice remained at an unsatisfac-
torily high level. a dose of 5 mg intra-
venous methotrexate was given on POSt-
operative day 21, with the assumption 
that an immunologic process was 
responsible for the cholestasis, 
Vascular rejection 
In the first of the twO liver xenograft 
recipients, six samples of the graft be-
tween the time of transplantation and 
autopsy on the 70th postoperative day 
were entirely free of artemis associated 
With vascular rejection I, Although there 
was a pOSitive conventional cross match 
preoperatively. and binding of IgM and 
IgG absorption and platelet sludging in 
the sinusoids by the xenograft immedi-
ately after reperlusion (as shown by 
direct Immunofluorescence). the im-
munoglobulins were largely absorbed 
from the graft tissues in the following 
days and weeks. except for IgG. which 
was pOSitive throughout. The second 
patient had eight xenograft biopSies from 
o to 26 days. rneluding the autopsy, The 
findings from these speCimens were sim-
ilar to those rn case I. with no evidence 
of relection-related artemis, 
Cellular relectlon and hepatitis 
One of the biopsies obtaIned from 
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patient I on day 12 had a mild focal cellu-
lar rejection by the conventional criteria 
used for hepatic allografts. while no defi-
nite evidence of cellular rejection was 
seen in any of the biopsy samples from 
patient 2 (Fig. 2). The biopsy obtained on 
day 64 from patient I showed a mild but 
diffuse increase in T (CD3+) and natural 
killer (NK; Leu-7·) cells in the sinusoids 
and septal bile ducts. but the findings 
were insufficient for an unequivocal diag-
nosis of rejection. Immunoperoxidase 
staining revealed no evidence of reinfec-
tion of the hepatic allograft with HBV in 
either case. 
Unexplained cho/estasis and microsteatosis 
A few T cells (CD4 < CDS) and even 
fewer NK cells in small bile ductules 
were given special attention because of 
the unexplained finding of intrahepatic 
cholestasis in the livers. which otherwise 
were normal (except for diffuse fine fatty 
infiltration). Although patient I was not 
jaundiced for nearly 2 months after the 
transplant. the canalicular enzymes 
(serum alkaline phosphatase and gamma-
glutamyl trans peptidase) were elevated 
astronomically (maximum 10000 inter-
national units for the alkaline phos-
phatase) from the second week onward. 
When icterus finally developed 55 days 
after transplantation. it was ascribed to 
partial obstruction of the reconstructed 
bile duct. even though the biliary-enteric 
anastomosis appeared satisfactory by 
cholangiography I , At autopsy. the entire 
biliary tree was filled With inspIssated 
bile. and most of the biliary ducts. which 
by this time had become bile lakes. were 
denuded of epithelium. This can be the 
end result with unrelieved obstructIon. 
but the alternative explanation is that 
the epithelial damage was the primary 
rather than a derivative event. 
A mechanical explanation for the 
cholestasls has been undermined by 
experience With the second recipient. 
whose xenograft showed the same 
microsteatosis and cholestasis on biopsy 
after 4 days despite an unquestionably 
adequate biliary anastomosis. This 
patient's pre-existing icterus was not 
relieved. the lowest bilirubin level being 8 
mg/dl on the fourth postoperative day. 
Bilirubin levels. which had fallen from 
17.3 mg/dl. increased thereafter to the 
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terminal concentration of 2S.3 mg% (Fig, 
I). In this patient, as in the first one. the 
jaundice was incompletely responsive to 
boluses and increased maintenance doses 
of prednisone. However. bile collected 
from an indwelling catheter abrupdy 
improved in color and consistency after 
some of the steroid bolus treatments. 
The liver as an optimal xenogra~ 
ImmunologiC advantages 
In the search for drugs that would 
Interdict the xenograft reaction after 
hamster-to-rat transplantation. two 
organs were used routinely for screen-
ing. One was the heart. which is consid-
ered immunologically difficult because it 
undergoes antibody rejection in unmodi-
fied rat recipients within 3 dayss,6, The 
other organ was the immunologically 
privileged liverS. which is easier to pro-
tect from rejection than the heart. 
shields concomitantly transplanted organs 
from rejection. including xenografts. and 
resists the attack of preformed xeno-
specific antigraft antibodies7• Because the 
liver presumably would not contribute 
to its own rejection. one factor in the 
antibody resistance could be its synthesis 
of most of the complement components'. 
In addition. most of the immunologic 
advantages of the liver have been linked 
to the high concentration in the liver of 
potentially migratory dendritic cells and 
other sessile tissue leukocytes that leave 
the transplanted hepatIC graft and pro-
duce systemic chimerism in the course 
of allograft acceptance and tolerance 
inductionS, In the hamster-to-rat experi-
ments9 and in patient I (Ref. I). 
chimerism was proved to be the same as 
seen in allografts. Consequently. an effort 
was made in patient 2 to augment the 
natural tolerogenicity of the liver with an 
infusion of baboon bone marrow cells 
shortly after revascularization of the 
liver. PCR (polymerase chain reaction) 
analysis revealed chimerism in all subse-
quent blood samples from patient 2. 
Metabolic questions 
In spite of its Immunologic advan-
tages. it remains to be determined if the 
baboon liver IS an approprrate organ for 
human xenotransplantatlon trials. The 
pOSSibility has not been disproved that a 
baboon liver could impose on a human 
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recipient a lethal interspecies metabolic 
difference. So far. there has been no 
direct evidence of this in connection 
with hepatic-based clotting factors and 
metabolites such as albumin. several 
globulins. uric acid and cholesterol. 
Nevertheless. the baboon liver was in-
capable of supporting more than 2 gm% 
serum concentration in the human en-
vironment. In addition. the cholestatic 
findings in the two patients could in 
some way be the product of a metabolic 
incompatibility rather than having an 
immunologic etiology. 
The hypoalbuminemia in both of the 
recipients was not considered surprising 
at the time because both of the baboon 
donors had serum albumin concentra-
tions in the 2-3 gm% range. These ani-
mals were accepted primarily because of 
their large size. even though they were 
both more than 15 years old. This may 
have been a mistake. There is no evi-
dence for a genetically imposed limit on 
albumin production by the baboon liver. 
and it is not clear why the albumin of the 
donors was so low since the other syn-
thetic hepatic functions. as well as the 
histopathologic features of the livers. 
were normal. Nevertheless. it is clear 
that hypoalbuminemia is not a 'normal' 
finding in this colony of domestically bred 
and reared animals. In a recent (unpub-
lished) study of 25 ostensibly healthy 
baboons housed at the Southwestern 
Foundation for Biomedical Research. San 
AntoniO. the mean serum albumin was 
3.5 !. 0.7 SO gm/dl (range 1.8-5.1). 
The baboon liver xenograft and beyond 
Additional liver transplant cases are 
not planned until the issue of metabolic 
compatibility is resolved. If metabolic 
incompatibility is the problem. the liver 
xenotransplantation experience will have 
provided a signal for a trial with an organ 
with simpler functions. such as the kid-
ney or heart. 
However. we do not recommend 
further human trials with any organ at 
present. We need to investigate the 
possibility that these twO livers were 
damaged by a mechanism similar to the 
Shwartzman or local Arthus reaction -
independent of classical rejection path-
ways. Nearly 25 years ago. working 
with Frank Dixon. we drew attention to 
the similarity of hyperacute renal rejec-
tion in patients with or without anti-
bodies to the Shwartzman and Arthus 
reactions. which depend upon comple-
ment activation with neutrophil partici-
pation I 0.11 . Since then. it has been 
shown that the complement patho-
genicity is derived from the stimulatory 
action of anaphylactotoxins (formed by 
the cleavage of C3 and C5) on mast 
cells and leukocytes - giving rise to a 
variety of pro inflammatory responses. 
Efforts to inhibit individual inflammatory 
mediators. such as platelet-activating 
factor. to prevent hyperacute xenograft 
rejection have been only marginally suc-
cessful 12. 
The harmful consequences of cleav-
age of C3 and C5 to these anaphylacto-
toxins is mitigated by complement 
receptor I (CR I). 
Table I. Levels of total serum complement (CH I 00). complement 
components (Ulml) and Immune complexes 
which binds to the 
complement frag-
ments. This knowl-
edge of the com-
plement cascade 
prompted the T-
Cell Sciences Cor-
poration. a bio-
tech company in 
Cambridge. Massa-
chusetts. to devel-
op a recombinant 
soluble human 
complement re-
ceptor (type I) 
that prevents both 
00)'1 
ponop 
II 
14 
17 
21 
26 
28 
J) 
&4 
CHIOO 
(>60) 
<21 
<21 
<21 
<21 
<21 
<21 
21 
43 
55 
66 
61 
« 
55 
55 
C3 
(83-177) 
NO 
NO 
NO 
NO 
NO 
NO 
NO 
NO 
64 
59 
51 
40 
58 
NO 
From Ref. I. NO. not detecable. 
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C4 
(15-45) 
NO 
NO 
NO 
NO 
NO 
NO 
ND 
NO 
17 
IS 
15 
13 
14 
NO 
C5 
(1)-20) 
NO 
NO 
NO 
NO 
NO 
NO 
NO 
NO 
20 
17 
II 
14 
15 
NO 
IC 
• (low) 
• (low) 
the classical and 
alternative com-
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plement pathways by binding to the ana-
phylactotoxins and promoting their 
degradation to inactive forms. By shut-
ting off the inflammatory mediators. the 
recombinant complement receptor can 
interdict the Arthus reaction. a simulated 
Shartzman reaction. and neutrophil-
mediated tissue injuryl3-15. 
In the next critical step. this recom-
binant molecule was shown. at relatively 
non-toxic doses. to delay the hyperacute 
rejection of heart allografts in highly sen-
sitized recipients - prolonging survival 
from 3 to 32 hours l6. The same drug in 
high doses prolonged xenograft survival 
in an extremely difficult guinea-pig-to-rat 
model from I 7 minutes to more than 12 
hours l7• 
Control of the complement patho-
genicity could be the missing piece in the 
treatment regimen used for our clinical 
xenotransplantations. In our first patient. 
Manez and Kelly found depleted total 
complement for the critical first 2 weeks 
while complement components C3. 4 
and 5 were undetectable (Table I). 
During this time. circulating immune 
complexes appeared. After this. the 
complement system settled down. This 
is the target of the complement recep-
tor. which is envisaged as an additional 
constituent of the drug cocktail used in 
our two clinical cases. Experiments to 
test this hypothesis are underway in 
experimental models. 
AIded by Prolect Grant No DR 29961 from the National 
Institutes 01 Health. Bethesda, Maryland. 
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